Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 4:03 PM ET


Company Overview of Heptares Therapeutics Ltd.

Company Overview

Heptares Therapeutics Ltd., a clinical-stage company, creates novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a range of human diseases. It offers GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, NCE discovery, and antibody discovery. The company was founded in 2007 and is based in Welwyn Garden City, United Kingdom. As of February 22, 2015, Heptares Therapeutics Ltd. operates as a subsidiary of Sosei Group Corporation.


Broadwater Road

Welwyn Garden City,  AL7 3AX

United Kingdom

Founded in 2007


44 17 0735 8628


44 17 0735 8640

Key Executives for Heptares Therapeutics Ltd.

Founder, Chairman and Chief Executive Officer
Age: 57
Founder, Chief Scientific Officer and Director
Age: 51
President of USA Operations
Age: 48
Chief Medical Officer and Vice President of Development
Age: 62
Chief Business Officer
Compensation as of Fiscal Year 2015.

Heptares Therapeutics Ltd. Key Developments

Heptares Therapeutics Wins $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse

Sosei Group Corporation announced that its subsidiary Heptares Therapeutics has been awarded a grant from the National Institute on Drug Abuse. The grant of approximately $5.5 million, with additional funding from Heptares, will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor for use in treating cocaine addiction and dependence, for which there are currently no approved treatments. The Orexin-1 receptor has been implicated in modulating cravings for a number of substances including cocaine, and antagonists of the receptor have been shown to be effective in models of cocaine addiction and dependence. Supported by the grant from NIDA, Heptares will progress lead molecules it has already identified to be selective antagonists of the Orexin-1 receptor to selection of a candidate drug, and then take this molecule through pre-clinical development. This project will be supported by the Heptares GPCR structure-based development platform, in particular making use of high-resolution X-ray structures Heptares has obtained of molecules bound to the closely related Orexin-1 and Orexin-2 receptors.

AstraZeneca and Heptares Therapeutics Partner to Develop New Immuno-Oncology Treatments

AstraZeneca has signed a licencing agreement with Heptares Therapeutics to develop novel immuno-oncology treatments. Under the deal, AstraZeneca will acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Both the firms will also work together to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

Heptares and AstraZeneca Enter Licensing Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers

Heptares Therapeutics announced that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will focus on exploring HTL-1071 and any additional compounds across a range of cancers, including in combination with its existing portfolio of immunotherapies. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating A2A receptors, adenosine stops T-cells within the immune system from proliferating and reduces their ability to destroy cancer cells. Blocking A2A receptors can therefore promote the anti-cancer response of T-cells within in the tumour microenvironment. Under the terms of the agreement, Heptares will grant AstraZeneca an exclusive license to research, develop, manufacture and commercialise HTL-1071. The companies will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy. Heptares will receive an upfront payment of $10 million and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events. Subject to successful completion of development and commercialisation milestones, Heptares is also eligible to receive more than $500 million, as well as up to double-digit tiered royalties on net sales.

Similar Private Companies By Industry

Company Name Region
Brabant Pharma Limited Europe
Surface Therapeutics Ltd. Europe
Relonchem Limited Europe
Heptares Therapeutics Ltd. Europe
AbbVie Ltd (UK) Europe

Recent Private Companies Transactions

August 6, 2015
Heptares Therapeutics Ltd., Global Rights of HTL-1071
February 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Heptares Therapeutics Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at